Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia

References

• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104(6):1624–1630.
   PubMed Web of Science ®Google Scholar
• Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997;24(1):70–82.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, GöKbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99(12):4379–4385.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589–596.
   PubMed Web of Science ®Google Scholar
• Camera A, Annino L, Chiurazzi F, et al. GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica. 2004;89(2):145–153.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136–5142.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
   PubMed Web of Science ®Google Scholar
• Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treatment Rev. 2003;29(1):3–10.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
   PubMed Web of Science ®Google Scholar
• Gong K, Xie J, Yi H, et al. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443(3):735–746.
   PubMed Web of Science ®Google Scholar
• Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–909.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma. 2017;58(6):1306–1319.
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–1771.
   PubMed Web of Science ®Google Scholar
• Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.
   PubMedGoogle Scholar
• Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489–4496.
   PubMed Web of Science ®Google Scholar
• McMahon CM, Luger SM. Relapsed T cell all: current approaches and new directions. Curr Hematol Malig Rep. 2019;14(2):83–93.
   PubMed Web of Science ®Google Scholar
• Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997;11(12):2039–2044.
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O'Brien S, et al. Augmented hyper-CVAD based on doseintensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11(1):54–59.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pullarkat V, Patel R, et al. An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. Med Oncol. 2013;30(4):744.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang L, Lin L, et al. A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Chin J Cancer Res. 2016;28(4):444–451.
   PubMed Web of Science ®Google Scholar
• Liu L, Qiu S, Liu Y, et al. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. Neoplasma 2016;63(2):193–200.
   PubMed Web of Science ®Google Scholar
• Zhang H, Dong L, Chen Q, et al. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. Leuk Res. 2017;56:29–35.
   PubMed Web of Science ®Google Scholar
• Dong M, Ning Z, Xing P, et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012;69(6):1413–1622.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Y, Zhou Y, et al. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenet. 2017;9(1):83.
   PubMedGoogle Scholar
• Shi P, Zhang L, Chen K, et al. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage. Pharmacogenomics. 2017;18(13):1259–1270.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou J, Wang L, et al. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 2013;8(8):e70522.
   PubMed Web of Science ®Google Scholar
• Zhang W, Shen H, Zhang Y, et al. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells. Cancer Med. 2019;8(5):2104–2113.
   PubMed Web of Science ®Google Scholar
• Brunvand MW, Carson J. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD. Hematol Oncol. 2018;36(1):340–343.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen G, Shen J, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in adults with relapsed/refractory acute myeloid leukemia: final results from a phase 1/2 study 615. In The 60th American Society of Hematology Annual Meeting; December 2; San Diego; 2018.
   Google Scholar
• Broux M, Prieto C, Demeyer S, et al. Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. Blood. 2019;134:1323–1336.
   PubMed Web of Science ®Google Scholar
• Jain N, Lamb AV, O’Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863–1869.
   PubMed Web of Science ®Google Scholar
• Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20(4):369–373.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–156.
   PubMed Web of Science ®Google Scholar
• Neumann M, Heesch S, Gökbuget N, et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012;2(1):e55.
   PubMed Web of Science ®Google Scholar
• Neumann M, Heesch S, Schlee C, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 2013;121(23):4749–4752.
   PubMed Web of Science ®Google Scholar